Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Affimed N.V.
  6. News
  7. Summary
    AFMD   NL0010872420

AFFIMED N.V.

(AFMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Affimed N : Q2 Loss Flat, Revenue Rises

09/08/2021 | 07:07am EDT


ę MT Newswires 2021
All news about AFFIMED N.V.
10/21AFFIMED N : Truist Securities Initiates Affimed at Buy Rating With $10 Price Target
MT
10/12AFFIMED N : SVB Leerink Adjusts Price Target on Affimed to $12 From $13, Maintains Outperf..
MT
10/04AFFIMED N : Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Ce..
AQ
10/01AFFIMED N : Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Ce..
GL
10/01Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cel..
GL
10/01Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cel..
CI
09/30AFFIMED N : Stifel Starts Affimed at Buy With $12 Price Target
MT
09/25AFFIMED N : 2021 Virtual Cantor Fitzgerald Healthcare Conference
PU
09/08AFFIMED N : Earnings Flash (AFMD) AFFIMED N.V. Posts Q2 Revenue $9.71M, vs. Street Est of ..
MT
09/08AFFIMED N : UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS (Form 6-K)
PU
More news
Analyst Recommendations on AFFIMED N.V.
More recommendations
Financials
Sales 2021 38,1 M 44,2 M 44,2 M
Net income 2021 -58,5 M -67,8 M -67,8 M
Net Debt 2021 - - -
P/E ratio 2021 -10,9x
Yield 2021 -
Capitalization 639 M 741 M 740 M
Capi. / Sales 2021 16,8x
Capi. / Sales 2022 13,1x
Nbr of Employees 153
Free-Float 97,2%
Chart AFFIMED N.V.
Duration : Period :
Affimed N.V. Technical Analysis Chart | AFMD | NL0010872420 | MarketScreener
Technical analysis trends AFFIMED N.V.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 5,33 €
Average target price 11,37 €
Spread / Average Target 113%
EPS Revisions
Managers and Directors
Adolf Hoess Chief Executive Officer
Angus W. Smith Chief Financial Officer
Thomas O. Hecht Chairman-Supervisory Board
Andreas Harstrick Chief Medical Officer
Arndt Schottelius Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
AFFIMED N.V.6.36%741
GILEAD SCIENCES, INC.16.15%84 845
BIONTECH SE261.78%71 229
WUXI APPTEC CO., LTD.24.08%64 399
REGENERON PHARMACEUTICALS19.27%59 906
VERTEX PHARMACEUTICALS-21.73%47 992